EUCTR2008-005802-37-HU进行中（未招募）不适用
An 8 day open-label, multiple-dose, multi-center study to evaluate the safety/tolerability and pharmacokinetics of aliskiren in hypertensive pediatric and adolescent patients 6 – 17 years of age.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female, 6 – 17 years of age (6 to less than 18 years of age at study completion)
- •2. Documented history of hypertension as defined in Section 5
- •3. Must be = 21.0 kg and = 100.0 kg at randomization (Visit 2)
- •4. Able to safely wash out antihypertensive therapy for 1 – 2 weeks
- •5. Patients who are eligible and able to participate in the study and whose parent(s)/guardian(s) consent in writing (written informed consent) to their doing so after the purpose and nature of the investigation has been clearly explained to them. An assent will be required for some patients depending upon their age and local requirements regarding assents. Informed consent must be obtained before any assessment is performed.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •For full list, please refer to the protocol.
- •1. Body weight of < 21 kg (46 lbs.) or > 100 kg (220 lbs.)
- •2. Inability to discontinue prior antihypertensive medication as required during the washout period
- •3. Any clinically significant abnormalities or clinically noteworthy abnormal laboratory values, including but not limited to the following:
- •AST/SGOT or ALT/SGPT > 1.5 times the upper limit of the normal (ULN) reference range
- •Total bilirubin > 1.5 times the upper limit of normal
- •Creatinine clearance <50 mL/min/1.73m² (based on the serum creatinine concentration obtained at the screening visit calculated using Modified Schwartz formula to estimate glomerular filtration rate [GFR])
- •WBC count < 3000/mm³
- •Platelet count < 100,000/mm³
- •Serum potassium > 5.3 mEq/L
- •Fasting glucose > 125 mg/dL (> 6.9 mmol/L) of the normal reference range
- •4. Renal artery stenosis
- •5. Current diagnosis of heart failure (NYHA Class II-IV)
- •6. msSBP = 25% above the 95th percentile for age, gender and height at Visit 2
- •7. Second or third degree heart block with or without a pacemaker
- •8. Atrial fibrillation or atrial flutter at Visit 1, or potentially life threatening or any symptomatic arrhythmia during the 12 months prior to Visit 1
- •9. Evidence of current symptomatic valvular disease
- •10. Previous solid organ transplantation or bone marrow transplant
- •11. Patients receiving immunosuppressant medication (e.g. cyclosporine, MMF, etc) other than inhaled/topical steroids, for any medical condition
- •12. Medical history of human immunodeficiency virus (HIV) and/or patient is concomitantly receiving anti-retroviral therapy
- •13. Medical history of hepatitis B and/or hepatitis C
- •14. Any clinically significant unstable medical condition or chronic disease that would put the patient at risk of experiencing an adverse event associated with the expected pharmacodynamic effects of the study medication
研究者
相似试验
进行中（未招募）
不适用
A study to look at the safety and pharmacokinetics of the drug aliskiren in children 6-17 years old who have high blood pressureMedDRA version: 14.1Level: PTClassification code 10020772Term: HypertensionSystem Organ Class: 10047065 - Vascular disordersHypertensionEUCTR2008-005802-37-Outside-EU/EEAovartis Pharma Services AG39
进行中（未招募）
不适用
An 8 day open-label, multiple-dose, multi-center study to evaluate the safety/tolerability and pharmacokinetics of aliskiren in hypertensive pediatric and adolescent patients 6 – 17 years of age.hypertensionEUCTR2008-005802-37-BEovartis Pharma Services AG36
进行中（未招募）
不适用
A multi-center, prospective, open-label, 8-weeks study to investigate the efficacy, safety and pharmacokinetics of certoparin (3000 IU anti-Xa bolus, with the option to titrate dose) in the prophylaxis of clotting in the extracorporeal circuit in patients undergoing chronic hemodialysisEUCTR2010-019200-23-DEovartis Pharma GmbH
进行中（未招募）
不适用
A study conducted in several countries and centres to compare the efficacy and safety of an 8 week treatment of patients with high blood pressure with aliskiren 300mg given once daily in fasted state compared to fed stateEssential hypertensionMedDRA version: 14.1Level: PTClassification code 10015488Term: Essential hypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-005297-36-ITOVARTIS FARMA568
进行中（未招募）
不适用
A study conducted in several countries and centres to compare the efficacy and safety of an 8 week treatment of patients with high blood pressure with aliskiren 300mg given once daily in fasted state compared to fed stateessential hypertensionMedDRA version: 14.0Level: PTClassification code 10015488Term: Essential hypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-005297-36-ESovartis Farmaceutica SA568